The company that makes Suboxone and Sublocade has agreed to a $294 million deal for rights to a new drug that could help eliminate cravings for a wide variety of substances, including opioids, alcohol, and tobacco.
Biotech company Indivior paid $10 million upfront and will provide additional backing of up to $284 million to develop the drug, called C4X3256.
The drug targets the neurotransmitter orexin—and specifically the OX1 receptor – and could be one of the first drugs to target eliminating cravings specifically, rather than blocking the effects of an addictive substance or satisfying cravings through a substitute.
Source: Fierce Biotech. Click here for more information.